The Pharmacogenomics of Contraception: Genetic Variants and Etonogestrel Pharmacokinetics study aims to research the pharmacology of commonly used contraceptives. The study will look specifically at the progestin etonogestrel and examine the relationship between genetic variants and hormone levels to pave the way for future research.
The study will enroll 700 women of reproductive age who have had an Etonogestrel (ENG) implant for over a year. They will have blood drawn and answer questions about their history when it comes to contraceptives and gynecological examinations. Researchers will then examine the samples with DNA extraction and a gene study. Participants will also be asked for consent to use the blood samples for future research.
- Women ages 18-45
- Have had an ENG contraceptive implant in place for 12-36 months
- Use of medications or supplements in the past four weeks which could impact serum ENG levels through inhibition or induction of CYP enzymes (specifically CYP-3A4)
- Medical conditions that could impact baseline liver function (e.g. hepatitis, cirrhosis)
- Body mass index (BMI) less than 18.5
University of Colorado Denver
Aurora, Colorado, United States, 80045
Contact: Lisa Powers email@example.com
Contact: Rebecca Seale Rebecca.Seale@ucdenver.edu
Principal Investigator: Aaron Lazorwitz, MD University of Colorado, Denver
University of Colorado, Denver
Society of Family Planning